Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

6 trials in Phase 3/4

Results Transparency

50%

5 of 10 completed trials have results

Key Signals

2 recruiting5 with results

Enrollment Performance

Analytics

Phase 3

5(41.7%)

Phase 2

3(25.0%)

N/A

2(16.7%)

Phase 4

1(8.3%)

Phase 1

1(8.3%)

12Total

Phase 3(5)

Phase 2(3)

N/A(2)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT06514612Phase 3Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

Role: lead

NCT07235592Not Yet Recruiting

PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

Role: lead

NCT06912802Recruiting

Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.

Role: lead

NCT04685109Not ApplicableActive Not Recruiting

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Role: lead

NCT04701086Not ApplicableCompleted

3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Role: lead

NCT04144413Phase 3Completed

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Role: lead

NCT04133311Phase 3Completed

A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

Role: lead

NCT03237936Phase 4Completed

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis

Role: lead

NCT01751126Phase 3Completed

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

Role: lead

NCT00328653Phase 2Completed

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Role: lead

NCT01254370Phase 2Completed

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

Role: lead

NCT00739349Phase 2Completed

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Role: lead

NCT00665106Phase 1Completed

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Role: lead

NCT00814515Phase 3Completed

Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome

Role: lead

All 14 trials loaded